* 5. oxygen saturation levels (spo2) ≤ 94% on room air. 6. female patients who are pregnant or breastfeeding. 7. patients with any active malignancy or undergoing active chemotherapy. 8. patients who are currently receiving or have received any investigational treatment for covid-19 within 30 days prior to screening. 9. in the opinion of the investigator, the participation of the patient in the study is not in the patient's best interest, or the patient has any medical condition that does not allow the study protocol to be followed safely. 10. patients with known allergies to any of the components used in the formulation of the interventions.

* 5. oxygen saturation levels (spo2) ≤ 94% on room air. 6. female patients who are pregnant or breastfeeding. 7. patients with any active malignancy or undergoing active chemotherapy. 8. patients who are currently receiving or have received any investigational treatment for covid-19 within 30 days prior to screening. 9. in the opinion of the investigator, the participation of the patient in the study is not in the patient's best interest, or the patient has any medical condition that does not allow the study protocol to be followed safely. 10. patients with known allergies to any of the components used in the formulation of the interventions.

- 5. oxygen saturation levels (spo2) ≤ 94% on room air. 6. female patients who are pregnant or breastfeeding. 7. patients with any active malignancy or undergoing active chemotherapy. 8. patients who are currently receiving or have received any investigational treatment for covid-19 within 30 days prior to screening. 9. in the opinion of the investigator, the participation of the patient in the study is not in the patient's best interest, or the patient has any medical condition that does not allow the study protocol to be followed safely. 10. patients with known allergies to any of the components used in the formulation of the interventions.

- 5. oxygen saturation levels (spo2) ≤ 94% on room air. 6. female patients who are pregnant or breastfeeding. 7. patients with any active malignancy or undergoing active chemotherapy. 8. patients who are currently receiving or have received any investigational treatment for covid-19 within 30 days prior to screening. 9. in the opinion of the investigator, the participation of the patient in the study is not in the patient's best interest, or the patient has any medical condition that does not allow the study protocol to be followed safely. 10. patients with known allergies to any of the components used in the formulation of the interventions.